Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ViroLogic (VLGC) -- Ignore unavailable to you. Want to Upgrade?

To: Jack Hartmann who wrote (41)	4/18/2001 10:35:46 PM
From: Ian@SI	Read Replies (1) \| Respond to of 59

It certainly wasn't Prudential helping out... ++++++++ 04/10 10:46 ViroLogic Inc. Price Target Cut at Prudential Vector 04/10 ViroLogic Inc. (VLGC US) was maintained ``strong buy'' by analyst John S Sonnier at Prudential Vector Healthcare Group. The 12-month price target was cut to $7 from $10 per share. 03/13 16:23 Virologic Inc. Reiterated `Strong Buy' at Prudential Vector Virologic Inc. (VLGC US) was reiterated ``strong buy'' by analyst John S Sonnier at Prudential Vector Healthcare Group. The price target is $10. 02/15 13:51 ViroLogic Inc. Reiterated `Strong Buy' at Prudential Vector ViroLogic Inc. (VLGC US) was reiterated ``strong buy'' by analyst John S Sonnier at Prudential Vector Healthcare Group. The 12-month target price is $25.00 per share. ++++++++++ Perhaps it was the insider buy. That was mentioned on another biotech thread. And this tends to be a relatively thinly traded stock lately. But we were 5 times normal volume today.